Ameriprise’s Elevation Oncology ELEV Stock Holding History

Ameriprise’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-294,326	Closed	-$108K	–	4090
2025 Q2	$108K	Sell	294,326 -4,464	-1%	-$1.49K	﹤0.01%	3878
2025 Q1	$77.4K	Sell	298,790 -145,249	-33%	-$82.9K	﹤0.01%	3908
2024 Q4	$250K	Buy	444,039 +3,550	+0.8%	+$2.1K	﹤0.01%	3787
2024 Q3	$264K	Buy	440,489 +299,160	+212%	+$444K	﹤0.01%	3682
2024 Q2	$382K	Buy	141,329 +121,026	+596%	+$456K	﹤0.01%	3516
2024 Q1	$104K	Buy	+20,303	New	+$65.8K	﹤0.01%	3780

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Ameriprise's ELEV Position: Q3 2025 in Review

Ameriprise sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 294,326 shares — an estimated $108K sold.

Ameriprise first reported a position in ELEV in Q1 2024 and held it in 6 quarters. The position peaked at $382K in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Ameriprise reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Ameriprise sold 294,326 Elevation Oncology shares in Q3 2025, an estimated $108K.
Ameriprise first reported a position in Elevation Oncology in Q1 2024 and held it in 6 quarters.
Ameriprise's Elevation Oncology position peaked at $382K in Q2 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.